About Cybin Inc. Common Stock
http://www.cybin.comClinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder.
CEO
Eric So
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public September 13, 2019
Method of going public IPO
Full time employees 50
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $367.63 M
52w High $10.72
52w Low $4.81
P/E -2.05
Volume 300.50K
Outstanding Shares 49.88M
About Cybin Inc. Common Stock
http://www.cybin.comClinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder.
CEO
Eric So
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public September 13, 2019
Method of going public IPO
Full time employees 50
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0